Home › CTI BioPharma Corp (CTIC) Upgraded at Zacks Investment Research
 

Keywords :   


CTI BioPharma Corp (CTIC) Upgraded at Zacks Investment Research

2015-12-29 06:13:09| Biotech - Topix.net

The brokerage currently has a $1.50 price objective on the biopharmaceutical company's stock. Zacks Investment Research 's price target would indicate a potential upside of 16.28% from the stock's current price.

Tags: research investment corp upgraded

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11Lawsuit over FDA's regulatory approval process for carbadox dismissed
07.11Hurricane Rafael Graphics
07.11Hurricane Rafael Forecast Discussion Number 16
07.11Hurricane Rafael Wind Speed Probabilities Number 16
07.11Hurricane Rafael Forecast Advisory Number 16
07.11Hurricane Rafael Public Advisory Number 16
07.11Summary for Hurricane Rafael (AT3/AL182024)
07.11Tropical Depression Fourteen-E Graphics
More »